Key result
DCB-based PCI is linked to ~6-point lower 2-year major cardiovascular events vs DES across all complex risk groups.
Why the study?
Evidence regarding the risk-stratified effectiveness of DCB-based PCI for de novo CAD remains limited, particularly in patients undergoing CHIP PCI.
Does a drug-coated balloon-based PCI strategy reduce the 2-year incidence of major adverse cardiovascular events compared to a drug-eluting stent-only PCI strategy in patients with de novo coronary artery disease across different CHIP risk categories?
Cohort (n=4,110)
Yes
Does a drug-coated balloon-based PCI strategy reduce the 2-year incidence of major adverse cardiovascular events compared to a drug-eluting stent-only PCI strategy in patients with de novo coronary artery disease across different CHIP risk categories?
Answers are grounded in this paper and cite their sources.
In this large multicenter propensity-matched registry, a DCB-based PCI strategy (standalone DCB or hybrid DCB/DES) was associated with significantly lower 2-year rates of MACE, TVR, and major bleeding compared to a DES-only strategy across all CHIP risk categories in de novo CAD.
Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI). Aims To compare the efficacy and safety of DCB‐based PCI versus DES‐only PCI for de novo CAD across CHIP risk categories. Methods Patients treated with DCB alone or with a hybrid DCB/drug‐eluting stent (DES) strategy between 2010 and 2023 were retrospectively analyzed (DCB‐based group). The comparator group included patients treated exclusively with second‐generation DES from a Korean multicenter registry. The primary endpoint was the 2‐year incidence of major adverse cardiovascular events (MACE): cardiac death, myocardial infarction, target vessel revascularization (TVR), target lesion thrombosis, and major bleeding. Results Total 2022 propensity score‐matched pairs were stratified by CHIP score into low (0–2; 1660 pairs), intermediate (3–4; 304 pairs), and high (≥ 5; 91 pairs) risk groups. DCB‐only treatment accounted for 70.8% of the DCB‐based group, with hybrid approaches more frequent in higher‐risk patients. Two‐year MACE rates increased with CHIP risk in both groups, but remained consistently lower in the DCB‐based group: 5.3%, 6.3%, and 20.0% versus 10.9%, 16.9%, and 31.2% for DES‐only PCI (log‐rank p < 0.001). DCB‐based PCI was associated with lower MACE risk across all CHIP categories (all p < 0.05), with no significant interaction (p‐interaction = 0.819). TVR reduction was significant in the low‐to‐intermediate risk (p‐interaction = 0.056), and major bleeding declined with increasing CHIP risk, most notably in the high‐risk group (p‐interaction = 0.044). Conclusions DCB‐based PCI was associated with significantly lower 2‐year MACE rates across all CHIP risk categories and may offer a potential alternative to DES‐only strategies in selective patients. Clinical trial registration number REAL‐DCB registry (NCT04619277), PTRG‐DES registry (NCT04734028).
No takes yet. Share an insight, caveat, or question.
Kang et al. (2026) conducted a cohort in De novo coronary artery disease undergoing PCI across CHIP risk categories (n=4,110). Drug-coated balloon (DCB)-based PCI strategy (DCB alone or hybrid DCB/DES) vs. Second-generation drug-eluting stent (DES)-only PCI strategy was evaluated on 2-year major adverse cardiovascular events (MACE: composite of cardiac death, non-fatal myocardial infarction, target vessel revascularization, definite target lesion thrombosis, and major bleeding) (p=<0.001). DCB-based PCI was associated with lower 2-year major cardiovascular events than DES-only PCI overall and across low, intermediate, and high CHIP risk groups.
Synapse has enriched 10 related papers. Consider them for comparative context: